Bruno Giuseppe, Fasano Massimo, Saracino Annalisa, Volpe Anna, Bartolomeo Nicola, Ladisa Nicoletta, Maggi Paolo, Monno Laura, Angarano Gioacchino
Clinic of Infectious Diseases, University of Bari, Italy.
New Microbiol. 2015 Jan;38(1):21-7. Epub 2015 Jan 1.
Single nucleotide polymorphisms (SNPs) rs12979860 and rs8099917 near the interleukin 28B gene are predictors of virological response (SVR) to IFN-based therapy for monoinfected chronic hepatitis C patients. We retrospectively evaluated the impact of IL28B SNPs and other factors on SVR in a cohort of 102 HIV-1/HCV-coinfected patients treated with pegylated interferon-? (peg-INF?) and ribavirin. Data on baseline features and virological response at different time-points were collected. Overall, 89/102 patients (87%) were males, 44 (43%) of whom infected with HCV genotype 1; SVR was achieved by 50 patients (49%). A univariate logistic regression analysis demonstrated that rs129679860 SNP genotype CC (p<0.034), rs8099917 SNP genotype TT (p<0.01), HCV genotype 2 or 3 (p<0.0001), low HCV viral load (p<0.028) and RVR (rapid virological response) (p<0.0001) were associated with a higher likelihood of SVR. Multivariate analysis confirmed only RVR and HCV genotype as independent predictors of SVR. In a real life setting, the importance of RVR and IL28B SNPs was confirmed as predictive of SVR to identify patients with a higher likelihood of SVR to Peg-INF?+RBV, and also to designate a deferred therapy for patients with a low likelihood of SVR for whom it is preferable to wait for more successful options.
白细胞介素28B基因附近的单核苷酸多态性(SNP)rs12979860和rs8099917是单纯感染的慢性丙型肝炎患者接受基于干扰素治疗后病毒学应答(SVR)的预测指标。我们回顾性评估了白细胞介素28B单核苷酸多态性及其他因素对102例接受聚乙二醇化干扰素-α(peg-INF-α)和利巴韦林治疗的HIV-1/HCV合并感染患者SVR的影响。收集了不同时间点的基线特征和病毒学应答数据。总体而言,102例患者中有89例(87%)为男性,其中44例(43%)感染丙型肝炎病毒1型;50例患者(49%)实现了SVR。单因素逻辑回归分析表明,rs129679860 SNP基因型CC(p<0.034)、rs8099917 SNP基因型TT(p<0.01)、丙型肝炎病毒基因型2或3(p<0.0001)、低丙型肝炎病毒载量(p<0.028)和快速病毒学应答(RVR)(p<0.0001)与SVR可能性较高相关。多因素分析仅证实RVR和丙型肝炎病毒基因型是SVR的独立预测指标。在实际临床环境中,RVR和白细胞介素28B单核苷酸多态性作为SVR预测指标的重要性得到了证实,可用于识别接受聚乙二醇化干扰素-α+利巴韦林治疗时SVR可能性较高的患者,也可为SVR可能性较低且更适合等待更有效治疗方案的患者指定延迟治疗。